NCT03305133 - Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2017

Primary Completion Date

September 14, 2018

Study Completion Date

October 30, 2018

Conditions

Large Cell Lung CancerNeuroendocrine Carcinoma of Lung (Diagnosis)

Interventions

OTHER

Immunohistochemistry

The slides which allowed the large cell neuroendocrine carcinoma diagnosis will be re-read centrally.

Trial Locations (28)

13100

Site 12, Aix-en-Provence

13274

Site 06, Marseille

14000

Site 43, Caen

20200

Site 05, Bastia

24019

Site 19, Périgueux

29200

Centre Hospitalier du Morvan, Brest

45032

Site 42, Orléans

49033

Centre Hospitalier Universitaire, Angers

51092

Site 02, Reims

60021

Site 22, Beauvais

63000

Site 48, Clermont-Ferrand

69495

Centre Hospitalier Lyon Sud, Lyon

69655

Site 11, Villefranche-sur-Saône

75012

Hospital Saint Antoine, Paris

Site 26, Paris

76031

Site 18, Rouen

76233

Site 17, Rouen

76503

Site 32, Elbeuf

77108

Site 01, Meaux

78200

Site 25, Mantes-la-Jolie

83800

Site 14, Toulon

85000

Centre Hospitalier Les Oudairies, La Roche-sur-Yon

87042

Centre Hospitalier Universitaire DUPUYTREN, Limoges

Hospital du Cluzeau, Limoges

94010

Site 33, Créteil

95100

Centre Hospitalier D Argenteuil, Argenteuil

05000

Site 04, Gap

Unknown

Site 00, Limoges

All Listed Sponsors

lead

Groupe Francais De Pneumo-Cancerologie

OTHER